vs
Orthofix Medical Inc.（OFIX）与Tecnoglass Inc.（TGLS）财务数据对比。点击上方公司名可切换其他公司
Tecnoglass Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$245.3M vs $219.9M），Tecnoglass Inc.净利率更高（10.6% vs -1.0%，领先11.7%），Tecnoglass Inc.同比增速更快（2.4% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $11.4M），过去两年Tecnoglass Inc.的营收复合增速更高（12.8% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Tecnoglass Inc.是一家领先的建筑玻璃、铝制门窗及相关建材生产商，主要服务北美及拉美地区的住宅和商业建筑领域，为新建及翻新项目提供定制化、高能效的建筑解决方案。
OFIX vs TGLS — 直观对比
营收规模更大
TGLS
是对方的1.1倍
$219.9M
营收增速更快
TGLS
高出0.4%
2.0%
净利率更高
TGLS
高出11.7%
-1.0%
自由现金流更多
OFIX
多$5.4M
$11.4M
两年增速更快
TGLS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $245.3M |
| 净利润 | $-2.2M | $26.1M |
| 毛利率 | 71.1% | 40.0% |
| 营业利润率 | 0.2% | 18.3% |
| 净利率 | -1.0% | 10.6% |
| 营收同比 | 2.0% | 2.4% |
| 净利润同比 | 92.4% | -44.5% |
| 每股收益（稀释后） | $-0.05 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTGLS
| Q4 25 | $219.9M | $245.3M | ||
| Q3 25 | $205.6M | $260.5M | ||
| Q2 25 | $203.1M | $255.5M | ||
| Q1 25 | $193.6M | $222.3M | ||
| Q4 24 | $215.7M | $239.6M | ||
| Q3 24 | $196.6M | $238.3M | ||
| Q2 24 | $198.6M | $219.7M | ||
| Q1 24 | $188.6M | $192.6M |
净利润OFIXTGLS
| Q4 25 | $-2.2M | $26.1M | ||
| Q3 25 | $-22.8M | $47.2M | ||
| Q2 25 | $-14.1M | $44.1M | ||
| Q1 25 | $-53.1M | $42.2M | ||
| Q4 24 | $-29.1M | $47.0M | ||
| Q3 24 | $-27.4M | $49.5M | ||
| Q2 24 | $-33.4M | $35.0M | ||
| Q1 24 | $-36.0M | $29.7M |
毛利率OFIXTGLS
| Q4 25 | 71.1% | 40.0% | ||
| Q3 25 | 72.2% | 42.7% | ||
| Q2 25 | 68.7% | 44.7% | ||
| Q1 25 | 62.8% | 43.9% | ||
| Q4 24 | 69.0% | 44.5% | ||
| Q3 24 | 68.7% | 45.8% | ||
| Q2 24 | 67.8% | 40.8% | ||
| Q1 24 | 67.5% | 38.8% |
营业利润率OFIXTGLS
| Q4 25 | 0.2% | 18.3% | ||
| Q3 25 | -8.3% | 25.1% | ||
| Q2 25 | -7.9% | 24.0% | ||
| Q1 25 | -25.2% | 26.7% | ||
| Q4 24 | -5.3% | 28.0% | ||
| Q3 24 | -9.6% | 28.4% | ||
| Q2 24 | -12.5% | 23.3% | ||
| Q1 24 | -15.6% | 21.3% |
净利率OFIXTGLS
| Q4 25 | -1.0% | 10.6% | ||
| Q3 25 | -11.1% | 18.1% | ||
| Q2 25 | -6.9% | 17.3% | ||
| Q1 25 | -27.4% | 19.0% | ||
| Q4 24 | -13.5% | 19.6% | ||
| Q3 24 | -13.9% | 20.8% | ||
| Q2 24 | -16.8% | 15.9% | ||
| Q1 24 | -19.1% | 15.4% |
每股收益（稀释后）OFIXTGLS
| Q4 25 | $-0.05 | $0.57 | ||
| Q3 25 | $-0.57 | $1.01 | ||
| Q2 25 | $-0.36 | $0.94 | ||
| Q1 25 | $-1.35 | $0.90 | ||
| Q4 24 | $-0.76 | $1.00 | ||
| Q3 24 | $-0.71 | $1.05 | ||
| Q2 24 | $-0.88 | $0.75 | ||
| Q1 24 | $-0.95 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $104.1M |
| 总债务越低越好 | — | $174.4M |
| 股东权益账面价值 | $450.0M | $713.1M |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资OFIXTGLS
| Q4 25 | $82.0M | $104.1M | ||
| Q3 25 | $62.9M | $127.1M | ||
| Q2 25 | $65.6M | $140.9M | ||
| Q1 25 | $58.0M | $160.2M | ||
| Q4 24 | $83.2M | $137.5M | ||
| Q3 24 | $30.1M | $124.8M | ||
| Q2 24 | $26.4M | $129.5M | ||
| Q1 24 | $27.0M | $138.8M |
总债务OFIXTGLS
| Q4 25 | — | $174.4M | ||
| Q3 25 | $157.2M | $114.7M | ||
| Q2 25 | $157.0M | $110.6M | ||
| Q1 25 | $156.9M | $110.6M | ||
| Q4 24 | $157.0M | $111.1M | ||
| Q3 24 | $118.5M | $126.8M | ||
| Q2 24 | $118.0M | $144.7M | ||
| Q1 24 | $118.2M | $160.9M |
股东权益OFIXTGLS
| Q4 25 | $450.0M | $713.1M | ||
| Q3 25 | $442.5M | $764.0M | ||
| Q2 25 | $458.3M | $736.0M | ||
| Q1 25 | $458.3M | $685.1M | ||
| Q4 24 | $503.1M | $631.2M | ||
| Q3 24 | $525.9M | $613.3M | ||
| Q2 24 | $546.0M | $574.8M | ||
| Q1 24 | $570.3M | $573.6M |
总资产OFIXTGLS
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.2B | ||
| Q1 25 | $823.1M | $1.1B | ||
| Q4 24 | $893.3M | $1.0B | ||
| Q3 24 | $867.9M | $996.3M | ||
| Q2 24 | $882.0M | $942.5M | ||
| Q1 24 | $906.0M | $981.6M |
负债/权益比OFIXTGLS
| Q4 25 | — | 0.24× | ||
| Q3 25 | 0.36× | 0.15× | ||
| Q2 25 | 0.34× | 0.15× | ||
| Q1 25 | 0.34× | 0.16× | ||
| Q4 24 | 0.31× | 0.18× | ||
| Q3 24 | 0.23× | 0.21× | ||
| Q2 24 | 0.22× | 0.25× | ||
| Q1 24 | 0.21× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $31.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $11.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 4.7% |
| 资本支出强度资本支出/营收 | 4.9% | 8.0% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $34.5M |
8季度趋势，按日历期对齐
经营现金流OFIXTGLS
| Q4 25 | $27.7M | $31.0M | ||
| Q3 25 | $12.4M | $40.0M | ||
| Q2 25 | $11.6M | $17.9M | ||
| Q1 25 | $-18.4M | $46.9M | ||
| Q4 24 | $23.7M | $61.1M | ||
| Q3 24 | $11.7M | $41.5M | ||
| Q2 24 | $9.0M | $34.5M | ||
| Q1 24 | $-18.6M | $33.4M |
自由现金流OFIXTGLS
| Q4 25 | $16.8M | $11.4M | ||
| Q3 25 | $2.5M | $21.2M | ||
| Q2 25 | $4.5M | $-14.7M | ||
| Q1 25 | $-25.1M | $16.5M | ||
| Q4 24 | $15.2M | $35.4M | ||
| Q3 24 | $6.3M | $17.8M | ||
| Q2 24 | $-360.0K | $14.2M | ||
| Q1 24 | $-29.1M | $23.6M |
自由现金流率OFIXTGLS
| Q4 25 | 7.6% | 4.7% | ||
| Q3 25 | 1.2% | 8.2% | ||
| Q2 25 | 2.2% | -5.7% | ||
| Q1 25 | -13.0% | 7.4% | ||
| Q4 24 | 7.0% | 14.8% | ||
| Q3 24 | 3.2% | 7.5% | ||
| Q2 24 | -0.2% | 6.5% | ||
| Q1 24 | -15.4% | 12.2% |
资本支出强度OFIXTGLS
| Q4 25 | 4.9% | 8.0% | ||
| Q3 25 | 4.8% | 7.2% | ||
| Q2 25 | 3.5% | 12.7% | ||
| Q1 25 | 3.5% | 13.7% | ||
| Q4 24 | 4.0% | 10.7% | ||
| Q3 24 | 2.7% | 9.9% | ||
| Q2 24 | 4.7% | 9.2% | ||
| Q1 24 | 5.6% | 5.1% |
现金转化率OFIXTGLS
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
